Frank Kung - 07 May 2024 Form 4 Insider Report for AMYRIS, INC.

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
07 May 2024, 20:12:40 UTC
Prior SEC filing
23 Sep 2022
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Frank Kung

Key filing fact

Frank Kung filed Form 4 for AMYRIS, INC. on 07 May 2024.

Key facts

  • This page summarizes Frank Kung's Form 4 filing for AMYRIS, INC..
  • 3 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 07 May 2024, 20:12.

Change

  • Previous filing in this sequence was filed on 23 Sep 2022.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AMRS transaction

Common Stock

Other

Transaction value
$0
Shares
-6,796,205
Change %
-100%
Price
$0.000000*
Shares after
0
Date
07 May 2024
Ownership
By Vivo Capital Fund VIII, L.P.
Footnotes
F1, F2
AMRS transaction

Common Stock

Other

Transaction value
$0
Shares
-938,416
Change %
-100%
Price
$0.000000*
Shares after
0
Date
07 May 2024
Ownership
By Vivo Capital Surplus Fund VIII, L.P.
Footnotes
F1, F2
AMRS transaction

Common Stock

Other

Transaction value
$0
Shares
-16,207
Change %
-100%
Price
$0.000000*
Shares after
0
Date
07 May 2024
Ownership
By Vivo Capital LLC
Footnotes
F1, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Frank Kung is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Pursuant to the Issuer's Third Amended Joint Plan of Reorganization Pursuant to Chapter 11 of the Bankruptcy Code, which was confirmed by the United States Bankruptcy Court for the District of Delaware on February 7, 2024 and became effective on May 7, 2024, each share of the Issuer's common stock and options to purchase the Issuer's common stock outstanding prior to the Issuer's emergence from bankruptcy were cancelled for no value.

Footnote F2

The General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. is Vivo Capital VIII, LLC, of which the Reporting Person is a voting member. The Reporting Person may be deemed to share voting and dispositive power over these shares with four (4) other voting members. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported shares for purposes of Section 16 or for any other purposes.

Footnote F3

Pursuant to an agreement dated November 2, 2017 between the Reporting Person and Vivo Capital LLC ("Vivo Capital"), the Reporting Person agreed to remit the equity compensation received under Issuer's non-employee director compensation program to Vivo Capital if and when such equity compensation becomes vested and/or exercised.

SEC remarks

In August 2023, pursuant to an agreement between the Reporting Person and the Issuer, the Reporting Person forfeited all unvested restricted stock unit awards and stock option awards granted pursuant to the Issuer's Non-Employee Director Compensation Program.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .